Editors' Note: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In this issue of Neurology®, Dr. Buciuc et al. describe the case of a patient with suspected Alzheimer disease and progressive auditory verbal agnosia. The clinical diagnosis is supported by nicely rendered [18F]-fluorodeoxyglucose PET imaging demonstrating hypometabolism in Heschl gyrus (primary auditory cortex), which corresponds with the patient's auditory verbal agnosia. The diagnosis of Alzheimer disease was reached on the basis of radiographic evidence of cortical atrophy with increased flortaucipir uptake in the bilateral temporal lobes (reflecting tau accumulation) and β-amyloid deposition on PET imaging, in the absence of other cognitive impairment. In response, Dr. Dasheiff commends the imaging findings and biologic explanation of this patient's condition; however, Dr. Dasheiff questions the diagnosis of Alzheimer disease given the lack of clinical pathology. The DSM-5 currently requires longitudinal follow-up and confirmation of progressive impairment in one or more cognitive domains to make the diagnosis of Alzheimer disease. The authors emphasize that their findings are consistent with Alzheimer pathology; however, they cannot confirm that an alternative tauopathy (or other clinical pathology) may account for this patient's neuroimaging and clinical manifestations.
In this issue of Neurology®, Dr. Buciuc et al. describe the case of a patient with suspected Alzheimer disease and progressive auditory verbal agnosia. The clinical diagnosis is supported by nicely rendered [18F]-fluorodeoxyglucose PET imaging demonstrating hypometabolism in Heschl gyrus (primary auditory cortex), which corresponds with the patient's auditory verbal agnosia. The diagnosis of Alzheimer disease was reached on the basis of radiographic evidence of cortical atrophy with increased flortaucipir uptake in the bilateral temporal lobes (reflecting tau accumulation) and β-amyloid deposition on PET imaging, in the absence of other cognitive impairment. In response, Dr. Dasheiff commends the imaging findings and biologic explanation of this patient's condition; however, Dr. Dasheiff questions the diagnosis of Alzheimer disease given the lack of clinical pathology. The DSM-5 currently requires longitudinal follow-up and confirmation of progressive impairment in one or more cognitive domains to make the diagnosis of Alzheimer disease. The authors emphasize that their findings are consistent with Alzheimer pathology; however, they cannot confirm that an alternative tauopathy (or other clinical pathology) may account for this patient's neuroimaging and clinical manifestations.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.